Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, cefalosporanic acid derivatives | 526 | 50370-12-2 |
Dose | Unit | Route |
---|---|---|
2 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Bocci G, Oprea TI, Benet LZ |
S (Water solubility) | 1 mg/mL | Bocci G, Oprea TI, Benet LZ |
EoM (Fraction excreted unchanged in urine) | 93 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 78.62 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 95 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.23 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.39 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.10 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 17, 1978 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cross sensitivity reaction | 384.50 | 26.84 | 69 | 2803 | 2093 | 63484057 |
Type IV hypersensitivity reaction | 247.76 | 26.84 | 50 | 2822 | 2848 | 63483302 |
Drug hypersensitivity | 107.62 | 26.84 | 98 | 2774 | 310589 | 63175561 |
Nasal oedema | 105.02 | 26.84 | 22 | 2850 | 1500 | 63484650 |
Rash maculo-papular | 104.71 | 26.84 | 43 | 2829 | 31853 | 63454297 |
Oedema | 73.69 | 26.84 | 49 | 2823 | 97573 | 63388577 |
Urticaria thermal | 58.53 | 26.84 | 11 | 2861 | 428 | 63485722 |
Asthma | 53.47 | 26.84 | 45 | 2827 | 127516 | 63358634 |
Respiratory tract infection | 52.40 | 26.84 | 29 | 2843 | 41454 | 63444696 |
Administration site erythema | 46.72 | 26.84 | 10 | 2862 | 755 | 63485395 |
Vitamin B12 deficiency | 35.21 | 26.84 | 12 | 2860 | 5291 | 63480859 |
Pigmentation disorder | 32.78 | 26.84 | 11 | 2861 | 4628 | 63481522 |
Scratch | 32.71 | 26.84 | 12 | 2860 | 6553 | 63479597 |
Wheezing | 32.55 | 26.84 | 30 | 2842 | 95565 | 63390585 |
Cough | 31.26 | 26.84 | 51 | 2821 | 292692 | 63193458 |
Pain | 31.01 | 26.84 | 88 | 2784 | 740540 | 62745610 |
Skin plaque | 29.95 | 26.84 | 12 | 2860 | 8308 | 63477842 |
Iodine allergy | 29.86 | 26.84 | 7 | 2865 | 797 | 63485353 |
Dizziness postural | 27.80 | 26.84 | 11 | 2861 | 7365 | 63478785 |
Chest pain | 27.75 | 26.84 | 41 | 2831 | 215918 | 63270232 |
Veillonella infection | 27.01 | 26.84 | 4 | 2868 | 34 | 63486116 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cross sensitivity reaction | 180.54 | 26.35 | 30 | 658 | 1367 | 34954876 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cross sensitivity reaction | 545.05 | 24.20 | 99 | 3135 | 3613 | 79737541 |
Type IV hypersensitivity reaction | 259.16 | 24.20 | 54 | 3180 | 4027 | 79737127 |
Nasal oedema | 98.94 | 24.20 | 21 | 3213 | 1703 | 79739451 |
Drug hypersensitivity | 93.50 | 24.20 | 85 | 3149 | 298831 | 79442323 |
Rash maculo-papular | 88.90 | 24.20 | 44 | 3190 | 56034 | 79685120 |
Oedema | 78.96 | 24.20 | 53 | 3181 | 119527 | 79621627 |
Asthma | 68.58 | 24.20 | 51 | 3183 | 135044 | 79606110 |
Urticaria thermal | 59.58 | 24.20 | 11 | 3223 | 434 | 79740720 |
Administration site erythema | 55.02 | 24.20 | 10 | 3224 | 361 | 79740793 |
Respiratory tract infection | 45.69 | 24.20 | 27 | 3207 | 48662 | 79692492 |
Drug reaction with eosinophilia and systemic symptoms | 38.83 | 24.20 | 27 | 3207 | 64217 | 79676937 |
Pain | 36.80 | 24.20 | 85 | 3149 | 703717 | 79037437 |
Erythema | 36.41 | 24.20 | 45 | 3189 | 223245 | 79517909 |
Pigmentation disorder | 31.89 | 24.20 | 11 | 3223 | 5607 | 79735547 |
Scratch | 31.16 | 24.20 | 12 | 3222 | 8351 | 79732803 |
Toxic epidermal necrolysis | 29.93 | 24.20 | 20 | 3214 | 44561 | 79696593 |
Urticaria | 29.65 | 24.20 | 37 | 3197 | 185164 | 79555990 |
Vitamin B12 deficiency | 29.17 | 24.20 | 11 | 3223 | 7230 | 79733924 |
Skin plaque | 28.24 | 24.20 | 12 | 3222 | 10733 | 79730421 |
Cough | 26.92 | 24.20 | 51 | 3183 | 366738 | 79374416 |
Wheezing | 26.60 | 24.20 | 28 | 3206 | 116636 | 79624518 |
Veillonella infection | 26.27 | 24.20 | 4 | 3230 | 47 | 79741107 |
Anaphylactic reaction | 24.45 | 24.20 | 23 | 3211 | 83720 | 79657434 |
Secretion discharge | 24.40 | 24.20 | 12 | 3222 | 15010 | 79726144 |
Dizziness postural | 24.21 | 24.20 | 11 | 3223 | 11538 | 79729616 |
None
Source | Code | Description |
---|---|---|
ATC | J01DB05 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Streptococcal tonsillitis | indication | 41582007 | |
Klebsiella cystitis | indication | 60867007 | |
Urinary tract infectious disease | indication | 68566005 | |
Tonsillitis | indication | 90176007 | DOID:10456 |
Escherichia coli urinary tract infection | indication | 301011002 | |
Proteus urinary tract infection | indication | 301012009 | |
Streptococcus pyogenes infection | indication | 302809008 | |
Infection due to Staphylococcus aureus | indication | 406602003 | |
Prevention of Bacterial Endocarditis | off-label use | ||
Impaired renal function disorder | contraindication | 197663003 | |
Pseudomembranous enterocolitis | contraindication | 397683000 |
Species | Use | Relation |
---|---|---|
Cats | Skin and soft tissue infections caused by susceptible strains of Staphylococcus aureus | Indication |
Cats | Genitourinary tract infections caused by Escherichia coli | Indication |
Cats | Genitourinary tract infections caused by Proteus species | Indication |
Cats | Genitourinary tract infections caused by Staphylococcus aureus | Indication |
Cats | Skin and soft tissue infections caused by Pasteurella multocida | Indication |
Cats | Skin and soft tissue infections caused by Staphylococcus epidermidis | Indication |
Cats | Skin and soft tissue infections caused by Streptococcus species | Indication |
Dogs | Skin and soft tissue infections caused by Staphylococcus aureus | Indication |
Dogs | Genitourinary tract infections caused by Escherichia coli | Indication |
Dogs | Genitourinary tract infections caused by Proteus species | Indication |
Dogs | Genitourinary tract infections caused by Staphylococcus aureus | Indication |
Product | Applicant | Ingredients |
---|---|---|
Cefa-Tabs | HQ Specialty Pharma Corp. | 1 |
Cefa-Drops | HQ Specialty Pharma Corp. | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.77 | acidic |
pKa2 | 9.72 | acidic |
pKa3 | 13.53 | acidic |
pKa4 | 7.63 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Solute carrier family 15 member 1 | Transporter | Ki | 2.14 | WOMBAT-PK | |||||
Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL |
ID | Source |
---|---|
4018151 | VUID |
N0000146488 | NUI |
D00257 | KEGG_DRUG |
119922-85-9 | SECONDARY_CAS_RN |
1297878 | RXNORM |
C0007538 | UMLSCUI |
CHEBI:53667 | CHEBI |
CHEMBL1644 | ChEMBL_ID |
DB01140 | DRUGBANK_ID |
D002434 | MESH_DESCRIPTOR_UI |
47965 | PUBCHEM_CID |
4831 | IUPHAR_LIGAND_ID |
280111G160 | UNII |
d00080 | MMSL |
13414000 | SNOMEDCT_US |
372651006 | SNOMEDCT_US |
4018151 | VANDF |
66592-87-8 | SECONDARY_CAS_RN |
004959 | NDDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3196 | CAPSULE | 500 mg | ORAL | ANDA | 22 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3196 | CAPSULE | 500 mg | ORAL | ANDA | 22 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-4059 | TABLET | 1000 mg | ORAL | ANDA | 23 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9766 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9767 | POWDER, FOR SUSPENSION | 250 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9947 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9948 | TABLET, FILM COATED | 1 g | ORAL | ANDA | 23 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-135 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
CEFADROXIL | Human Prescription Drug Label | 1 | 16590-043 | CAPSULE | 500 mg | ORAL | ANDA | 23 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 16714-388 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 16714-388 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 16714-389 | POWDER, FOR SUSPENSION | 250 mg | ORAL | ANDA | 21 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 16714-389 | POWDER, FOR SUSPENSION | 250 mg | ORAL | ANDA | 21 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 16714-390 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 16714-390 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-427 | CAPSULE | 500 mg | ORAL | ANDA | 22 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-018 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-146 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
CEFADROXIL | Human Prescription Drug Label | 1 | 42549-504 | CAPSULE | 500 mg | ORAL | ANDA | 23 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-553 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-553 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-553 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-595 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-595 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-595 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45865-503 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0580 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0580 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 50090-1915 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 50090-6050 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |